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Background: Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a multifunctional Ig-like cell
adhesion molecule that has a wide range of biological functions. According to previous reports, serum CEACAM1 is
dysregulated in different malignant tumours and associated with tumour progression. However, the serum
CEACAM1 expression in non-small-cell lung carcinomas (NSCLC) is unclear. The different expression ratio of
CEACAM1-S and CEACAM1-L isoform has seldom been investigated in NSCLC. This research is intended to study
the serum CEACAM1 and the ratio of CEACAM1-S/L isoforms in NSCLC.
Methods: The expression of the serum CEACAM1 was determined by enzyme-linked immunosorbent assay. The
protein expression and the location of CEACAM1 in tumours were observed by immunohistochemical staining. The
CEACAM1 mRNA levels in tumour and normal adjacent tissues were measured using quantitative real-time PCR, and
the expression patterns and the rate of CEACAM1-S and CEACAM1-L were analysed by reverse transcription-PCR.
Results: Serum CEACAM1 levels were significantly higher in NSCLC patients compared with that from normal healthy
controls (P <0.0001). 17 patients (81%) among 21 showed high expression of CEACAM1 by immunohistochemical
staining. Although no significant differences were found between tumour and normal tissues on mRNA expression
levels of CEACAM1 (P >0.05), the CEACAM1-S and the CEACAM1-S/L (S: L) ratios were significantly higher in tumour
than normal tissues (P <0.05).
Conclusions: Our data indicated that the serum levels of CEACAM1 could discriminate lung cancer patients from
health donors and that CEACAM1 might be a useful marker in early diagnosis of NSCLC. Moreover, our results showed
that the expression patterns of CEACAM1 isoforms could be changed during oncogenesis, even when total CEACAM1
in tumour tissues did not show significant changes. Our study suggested that the expression ratios of CEACAM1-S/
CEACAM1-L might be a better diagnostic indicator in NSCLC than the quantitative changes of CEACAM1.
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Lung cancer is currently the most common cancer in
terms of incidence and mortality worldwide [1]. Non-
small-cell lung carcinoma (NSCLC) accounts for over
80% of all histological lung cancers. Approximately 40%
of patients with NSCLC show locally advanced disease
with lymph node involvement at the time of diagnosis.
Thus, early NSCLC detection is highly valuable.
Carcinoembryonic antigen-related cell adhesion mol-
ecule 1 (CEACAM1), a single-pass transmembrane type I
glycoprotein, belongs to the carcinoembryonic antigen
(CEA) family. This protein is widely expressed in a variety
of proliferating and quiescent epithelial, endothelial, and
haematopoietic cells [2]. CEACAM1 is involved in a var-
iety of cell biological events, such as morphogenesis [3],
vasculogenesis [4], cell motility [5], cell proliferation [6,7],
infection, and inflammation [2]. CEACAM1 exists in 11
known isoforms, resulting from differential splicing and
proteolytic processing. The functions of the 11 known
CEACAM1 isoforms are divided based on the isoforms
CEACAM1-L and CEACAM1-S, which are named based
on the length of their cytoplasmic tail. The L-form con-
tains two immunoreceptor tyrosine-based inhibitory mo-
tifs (ITIMs), whereas the S-form does not. Both isoforms
are co-expressed in most CEACAM1-expressing tissues,
and the ratio between the two isoforms determines the
signalling outcome [8-12].
Aberrant CEACAM1 expression is associated with
tumour progression and has been found in a variety of
human malignancies. Previous reports showed that
CEACAM1 is down-regulated in many types of tumours,
such as colorectal carcinoma [13], hepatoma [14], breast
carcinoma [15], renal cell carcinoma [16] and prostate car-
cinoma [17]. Additionally, the inhibition of tumour growth
upon CEACAM1 re-expression in tumour cells was
reported to led to the original definition of CEACAM1 as
a tumour suppressor [18]. In contrast, CEACAM1 was
also found to be up-regulated in malignant melanoma
[19], thyroid cancer [20] and gastric adenocarcinoma. Al-
though the published literature on CEACAM1 expression
in cancer is contradictory, most investigators agree that
these changes in expression offer an important indicator
for clinical diagnoses.
Recent reports have shown that the serum CEACAM1
level was increased in pancreatic adenocarcinoma [21]
and melanoma patients [19,22]. This increase was corre-
lated with disease progression, providing evidence for
the potential value of soluble CEACAM1 as a tumour
marker. In lung cancer, mainly immunohistochemical
evidence has accumulated indicating that epithelial
CEACAM1 expression is associated with tumour metas-
tasis and progression [23-26]. However, little informa-
tion exists concerning serum CEACAM1 in lung cancer.
This information would be valuable because currentlyavailable circulating tumour markers for lung cancer,
such as carcinoembryonic antigen (CEA) and neuron-
specific enolase (NSE), are not satisfactory, and the need
for better prognostic markers is urgent. It is therefore
necessary to evaluate the changes in serum CEACAM1
in the context of lung cancer.
In an exploratory phase (phase I) study [27] in which
the serum level of CEACAM1 was evaluated to determine
whether it could be used to discriminate lung cancer pa-
tients from health donors, we set our sample size as
recommended by Obuchowski et al. [28]. We compared
the serum level of CEACAM1 in NSCLC patients with
healthy donors and analyzed the location and expression
of CEACAM1 in primary tumour tissues by immunohis-
tochemical staining. Additionally, the CEACAM1 expres-
sion levels in lung cancer tissues together with adjacent
normal lung tissues were verified at the mRNA level from
the same serum providers in parallel using quantitative
real-time PCR. The CEACAM1 S/L isoform expression
patterns were verified by reverse transcription-PCR.
Methods
Serum and tissue samples
A total of 69 serum samples were included in this study,
including 35 samples that were collected from NSCLC pa-
tients before surgery (average age: 60, range: 34 to 78 years;
samples with any other disease outside the lungs were ex-
cluded) and 34 samples that were collected from sex- and
age-matched healthy volunteers who passed all of the rou-
tine medical examinations (e.g., blood tests, X-ray, and
computerised tomography test) without abnormal results.
Informed consent was obtained from all of the patients
who participated in the study, which was conducted with
the approval of the Ethics Committee of the Scientific and
Ethical Committee of Shanghai Jiao Tong University in ac-
cordance with the Helsinki declaration of 1975 (as revised
in 1983). All the patients were diagnosed with cancer for
the first time, and none previously received chemotherapy
or radiation therapy.
Briefly, the samples were maintained at room tem-
perature for approximately 30 minutes and then cen-
trifuged at 1,300 g at 4°C for 20 minutes. The serum was
then collected, divided into aliquots and frozen at -80°C
until analysis. We also collected 21 paired (tumour and
normal mucosa) tissue samples in parallel from the same
35 NSCLC patients mentioned above to assay by quantita-
tive real-time polymerase chain reaction (qRT-PCR). Dur-
ing the surgical removal of each tumour, an adjacent
section of normal mucosa was also removed for normal
background tissue following pathological confirmation
that it was free from tumour deposits. Tissues were
obtained and snap frozen in liquid nitrogen. Additionally,
13 of 21 pairs of tissues were analysed for CEACAM1
isoforms: 6 cases of adenocarcinoma, 5 cases of squamous
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and 1 case of a lymphoepithelioma-like carcinoma. De-
tailed clinical and pathological information of the samples
can be found in Additional file 1: Table S1.
Sandwich ELISA for serum CEACAM1
Serum CEACAM1 was analysed with enzyme-linked im-
munosorbent assay (ELISA) kits (RayBiotech, Atlanta,
GA, USA) according to the manufacturer's instructions.
Briefly, a 96-well microplate was precoated with anti-
human CEACAM1, which recognises the extracellular
domain (a.a. 35-428). Before use, all of the reagents and
samples were brought to room temperature (18-25°C).
The standard dilution series ranged from 20.58 to
15,000 pg/ml. First, 100 μl of each standard or serum
sample (1:100 prediluted) was added to the appropriate
wells and incubated for 2.5 hours at 24°C with gentle
shaking. After discarding the solution and washing 4
times, 100 μl of prepared biotinylated anti-human
CEACAM1 antibody was added to each well and incu-
bated for 1 hour. After washing away unbound
biotinylated antibody, 100 μl of horseradish peroxidase
(HRP)-conjugated streptavidin was pipetted into the
wells and incubated for 45 minutes, and 100 μl of
3,3’,5,5’-Tetramethylbenzidine (TMB) one-step substrate
reagent was added after 5 washes. Subsequently, 50 μl of
stop solution was added to each well, and the plate was
immediately read at 450 nm.
In addition, we assayed carcinoembryonic antigen (CEA;
ARCHITECT i2000 SR, Abbott, Chicago, IL, USA) and
neuron-specific enolase (NSE; cobas e601 Roche, Basel,
N.A., Switzerland) in all of the serum samples. The CEA
and NSE cut-off values were 5.0 and 17 ng/ml, respect-
ively. Tumour markers with serum values higher than the
cut-off were classified as positive, while those with values
lower than the cut-off were negative.
Immunohistochemical staining
To determine the expression and location of CEACAM1,
a total of 21 specimens were stained using immuno-
histochemistry method, which was performed on paraf
fin-embedded specimens with the mouse monoclonal
anti-CEACAM1 antibody (Abcam; 29H2, Cambridge, UK,
dilution: 1:75). Briefly, the sections were dewaxed, and en-
dogenous peroxidase was blocked by immersing the slides
in a 3% solution of hydrogen peroxide in methanol for
10 minutes followed by antigen retrieval. The slides were
microwaved for 10 minutes in 10 mmol/L citrate buffer,
pH 6.0. After washing 3 times in 1 mol/l phosphate-
buffered saline (PBS; pH 7.4) for 5 minutes, the sections
were blocked with normal rabbit serum in a humidity
chamber for 30 minutes at room temperature. The ex-
cess serum was rinsed off with 1 mol/l PBS, and the sec-
tions were incubated with primary antibodies in ahumidity chamber overnight at 4°C. The next morning,
sections were rinsed with PBS before incubation with the
biotinylated second antibody in a humidity chamber for
40 minutes at 37°C. After rinsing with PBS, the strep-
tavidin–peroxidase complex reagent (StrepABComplex/
HRP Duet, DAKO, Glostrup, Denmark) was added.
Diaminobenzidine and hydrogen peroxide were used for
visualisation. For negative controls, the primary antibody
was replaced with PBS.
All the 21 NSCLC were categorized into a high ex-
pression group (i.e., ≥ 66% positive tumour cells) and a
low expression group (i.e., < 66% positive tumour cells)
according to the percentage of positive tumour cells
[23,29,30] (Figure 1). The high or low classifications
were independently assigned by two experienced pathol-
ogists and consensus was achieved after discussion.
Quantitative real-time polymerase chain reaction for the
CEACAM1 RNA level
Total RNA was isolated using the TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s instructions. The purity and concentration of
RNA were determined with a spectrophotometer at
260 nm. Complementary DNA (cDNA) was generated by
the PrimeScriptW RT reagent Kit (Takara Biotechnology,
Otsu, Shiga, Japan). GAPDH was used as an internal con-
trol for each sample. Quantitative real-time PCR was
performed using specific primers (Table 1). Briefly, 1 μg of
total RNA was denatured for 5 minutes at 70°C and
cooled for 5 minutes on ice. Reverse transcriptase (RT)
was added to a total volume of 20 μl, and reverse transcrip-
tion was performed for 15 minutes at 37°C followed by
5 seconds at 85°C, according to the protocol recommended
by the manufacturer. The synthesised cDNA was either
used immediately for PCR amplification or stored at -20°C
for further analysis. Quantitative PCR was performed in a
total reaction volume of 20 μl per capillary in the
LightCycler format for 40 cycles (denaturation: 30 seconds
at 95°C, annealing: 20 seconds at 60°C, and extension:
15 seconds at 72°C). After PCR amplification, melting curve
analysis was performed to verify the specificity of the test.
Reverse transcription-PCR for the expression patterns of
CEACAM1 isoforms
The reverse transcription PCR primers as reported by
Wang et al. [31] and Gaur et al. [32] (Table 1) were
designed to distinguish the 408 bp (CEACAM1-L) and
355 bp (CEACAM1-S) CEACAM1 isoforms. The PCR
was performed in a total volume of 50 μl containing
0.25 μl of TaKaRa Ex Taq (5 U/μl), 5 μl of 10× Ex Taq
Buffer (Mg2+ Plus), 4 μl of dNTP mixture, 2 μl of cDNA
template, 1 μl of each forward and reverse primer and
ddH2O. After pre-denaturation at 94°C for 5 minutes,
the PCR cycling conditions for CEACAM1 and GAPDH
Figure 1 Immunohistochemical staining of CEACAM1 in primary NSCLC. (A) Representative CEACAM1 staining in tumour tissues. Arrows
indicate the positive staining of neoplastic epithelium cells (brown colour, 200 ×microscopic field). (B) No specific staining is visible in the section
of normal cells adjacent to the tumour samples (200 ×microscopic field).
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30 seconds, and 72°C for 30 seconds. The reaction was
performed with an Eppendorf thermal cycler (Eppendorf,
Hamburg, Germany). At the end of the reaction, the mix-
tures were loaded onto a 2% agarose gel and stained with
ethidium bromide prior to examination under UV light.
Statistical analysis
L-form CEACAM1 and S-form CEACAM1 levels were
represented as integral optical density (IOD) values with
Image Pro Plus V6.0 for Windows (Media Cybernetics,
Inc., Rockville, MD, USA). Briefly, after intensity rectifica-
tion, IODs were obtained as the ratio of sum optical dens-
ity (OD) to the sum area, which is proportional to the
quantity of RNA. Most of the data were not normally dis-
tributed. Thus, they were expressed as a median or a
range. The Mann–Whitney and Kruskal–Wallis tests were
used to determine the significance of two independent
groups and various groups, respectively. Nonparametric
receiver operating characteristic (ROC) curves in whichTable 1 Primer sequences for real-time PCR and reverse trans
Primer name








“*” The GenBank accession numbers NM_001712.4, NM_001184815.1, NM_001184815
CEACAM1 transcript variants 1, 2, 3, 4, 5, 6, respectively.the value for sensitivity is plotted against the false-positive
rate (1-specificity) were generated to assess the diagnostic
accuracy of serum CEACAM1. Receiver operating charac-
teristic (ROC) curves are measured to test whether the
area under the curve (AUC) of the ROC exceeds 0.5. If
not, no further assessment of the diagnostic test is
warranted. Statistical significance in this study was set at
P < 0.05, and all of the reported P values are 2-sided. All of
the analyses were performed with SPSS v.16 for Windows
(SPSS Inc., Chicago, IL, USA) or SigmaPlot V. 12 for
Windows (Systat Software Inc., San Jose, CA, USA).
Results
CEACAM1 serum levels
The clinical and pathological characteristics of patients are
shown in Table 2. The median serum CEACAM1 level
was significantly higher in patients with NSCLC compared
with normal healthy controls (P < 0.0001; Figure 2A). For
patients with NSCLC, the median CEACAM1 level was




: 5’-GCACCGTCAAGGCTGAGAAC-3’ 142 bp
: 5’-ATGGTGGTGAAGACGCCAGT-3’
:5’-GGTTGCTCTGATAGCAGTAG-3’ 408 bp (L-form)
: 5’-AGCCTGGAGATGCCTATTAG-3’ 355 bp (S-form)
5’-GGGAAGGTGAAGGTCGGAGTC-3’ 570 bp
:5’-AGGGGCCATCCACAGTCTTCT-3’
.1, NM_001184813.1, NM_001184816.1 and NM_001205344.1 correspond to
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226.80 ~ 490.11 ng/ml). Patients who were at an early
stage of disease (stage I and II disease) showed signifi-
cantly higher CEACAM1 levels than patients in stage
III and IV (P = 0.016; Table 2). Moreover, serum
CEACAM1 levels were significantly lower in female pa-
tients than in male patients (Table 2).
In multivariable logistic regression analysis, CEACAM1
levels significantly predicted NSCLC vs. normal control
(OR: 1.052; 95% CI: 1.022 ~ 1.083; P < 0.001) when adjusted
for age and gender effects. The ability of serum CEACAM1,
CEA and NSE to predict NSCLC was analysed by nonpara-
metric ROC analyses. When used to distinguish NSCLC
from normal healthy individuals, the AUCs for serum
CEACAM1, CEA and NSE were 0.96 (95% CI: 0.9148 ~
0.9995; P < 0.001), 0.91 (95% CI: 0.8454 ~ 0.9773; P < 0.001)
and 0.98 (95% CI: 0.9302 ~ 1.023; P < 0.001), respectively.













Stage Ia ~ IIb 19 56
Stage IIIa ~ IV 16 49
Grading
G1 ~ 2 14 54
G3 ~ 4 21 54
Histology




Node negative 13 56
Node positive 22 53
Invasion depth
pT1 ~ pT2 26 55
pT3 ~ pT4 9 51
*P < 0.05.
“**” 7th edition of the TNM classification of lung cancer by the International Associa
“***” Others represent 5 poorly differentiated carcinomas, 2 mixed histologies, 2 neYouden index), serum CEACAM1 had a sensitivity of 97%,
a specificity of 82%, a positive predictive value of 70%, and
a negative predictive value of 95% (Figure 2B, Additional
file 2: Table S2). Therefore, according to the AUC of the
ROC curve, CEACAM1 was better than CEA but did not
exceed NSE.
In the clinic, the cut off values for CEA and NSE
were set to 5 and 17 ng/ml, respectively. The cor-
responding diagnostic accuracy of CEACAM1, CEA
and NSE is summarised in Additional file 2: Table S2.
Generally, CEACAM1 had a significantly higher sen-
sitivity (97%) than CEA (29%, P < 0.05) and NSE (20%,
P < 0.05). However, CEA (97%) and NSE (97%) had bet-
ter specificity than CEACAM1 (82%), not significantly
(P > 0.05). The negative predictive value of CEACAM1
(95%) was higher compared with CEA (57%) and NSE
(54%), but the positive predictive value of CEACAM1
(70%) was lower than CEA (91%) and NSE (88%),levels and clinical parameters
CEACAM1
an (P50) Range P value
0.70 381.30 ~ 735.84 0.679
5.32 442.07 ~ 968.13
8.98 442.07 ~ 968.13 0.042*
3.95 381.30 ~ 735.84
9.89 381.30 ~ 674.69 0.619
8.34 442.07 ~ 968.13
6.04 381.03 ~ 968.13 0.016*
9.66 442.07 ~ 638.68
2.42 442.07 ~ 968.13 0.775
4.79 381.30 ~ 735.84
1.31 499.66 ~ 627.02 0.180
9.89 381.30 ~ 735.84
9.29 442.07 ~ 968.13
6.04 381.30 ~ 968.13 0.274
2.34 442.07 ~ 735.84
1.88 381.30 ~ 968.13 0.131
9.89 442.07 ~ 638.68
tion for the Study of Lung Cancer (IASLC).
uroendocrine carcinomas and 1 lymphoepithelioma-like carcinoma.
Figure 2 Individual CEACAM1 serum levels and receiver operator characteristic curves for NSCLC patients and normal controls. (A) The
serum CEACAM1 in patients with NSCLC and normal controls are plotted as a distribution (P < 0.001). (B) ROC curves generated from the serum
CEACAM1, CEA and NSE of 35 patients with NSCLC. The areas under the curves are 0.96, 0.91 and 0.98 for CEACAM1, CEA and NSE, respectively (P < 0.05).
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and NSE.CEACAM1 protein and mRNA expression in lung tissues
By immunohistochemical staining, we found that the
CEACAM1 expression was restricted to neoplastic epithe-
lium in all the specimens of 21 patients (Figure 1A). No
CEACAM1 expression was found in normal cells adjacent
to the tumours or in the negative controls (Figure 1B). Tu-
mours of 17 patients (81%) were classified as high expres-
sion (Figure 1A, i.e., ≥66% positive tumour cells), and
specimens of 4 patients (19%) were classified as low ex-
pression (Figure 1B, i.e., <66% positive tumour cells).
The 2-△Ct (-ΔCt = Ct, GAPDH-Ct, CEACAM1) method was
employed. Although 15 of 21 subjects showed higher
CEACAM1 mRNA levels in tumours compared to adja-
cent tumour-free tissues, no significant differences were
found between the mRNA expression of CEACAM1 in tu-
mours and normal tissues by the Wilcoxon signed-rank
test for 2 related samples (Figure 3A). Further studies of
CEACAM1 mRNA levels and the patient clinical and
pathological characteristics were shown in Table 3.
CEACAM1 mRNA levels were significantly higher in male
patients than in female patients (P = 0.028), which was
consistent with the serum protein levels (Table 2).
CEACAM1 mRNA levels also showed a significant
negative correlation with tumour invasive extension
(P = 0.039), which is in accordance with the serum protein
levels. In addition, patients with adenocarcinoma showed
higher CEACAM1 mRNA levels than squamous cell car-
cinoma or other types (P = 0.003). No other significantassociation was found between clinical characteristics and
CEACAM1 mRNA levels.
CEACAM1 isoform expression patterns
To determine whether the expression of CEACAM1-L
and CEACAM1-S are altered in primary NSCLC, we
analysed 13 pairs of primary tumour and normal lung tis-
sue specimens with the same PCR primers reported by
Gaur et al. [32] and Wang et al. [31]. The forward primer
is located in exon 6, and the reverse primer is located
within the 3’ untranslated region. Thus, the primers can
amplify a 408 bp fragment (CEACAM1-L) or a 355 bp
fragment (CEACAM1-S) simultaneously by inclusion or
exclusion of exon 7. As shown in Figure 3B, CEACAM1-S
was predominantly expressed in lung tumours tissues,
whereas the normal tissues predominantly expressed
CEACAM1-L. In total, 12 of 13 lung tumours had a
CEACAM1-S/CEACAM1-L (S: L) ratio greater than 1
(S-form > L-form), whereas normal lung tissue did not.
Further statistical data were consistent with this finding.
The CEACAM1-S and the CEACAM1-S/CEACAM1-L
(S: L) ratio was significantly higher in tumours than in
normal tissues (P = 0.023 for CEACAM1-S and 0.016 for
the CEACAM1-S/CEACAM1-L (S: L) ratio; Figure 3C
and 3D, Table 4). However, the expression of CEACAM1-
L did not show a marked difference between tumour and
normal tissue (Figure 3C, Table 4).
Discussion
CEACAM1 mediates various key signal transduction
pathways in tumour progression [8,33-35]. Reports indi-
cated that increased CEACAM1 is strongly associated
Figure 3 The S-form and L-form CEACAM1 mRNA expression level and patterns in NSCLC and normal tissues. (A) The expression level of
CEACAM1 mRNA in tumour tissues and normal tissues (P > 0.05). (B) ①. Representative RT-PCR data performed with total RNA extracts from 13
paired NSCLC specimens (T = tumour, N = normal). ②. Histogram depicting CEACAM1-S/CEACAM1-L (S: L) ratio for the 13 paired specimens in bar
graph quantified with Image Pro Plus program. Data represent the mean ± SD of at least three independent experiments. (C) The distribution of
integral optical density (IOD) values for CEACAM1-S form and L-form compared with GAPDH in 13 paired tumour and normal adjacent tissues
samples (T = tumour; N = normal). (D) The distribution of the CEACAM1-S/L ratio in 13 paired tumour and normal adjacent tissues samples
(P < 0.05).
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gression, and its expression could be determined in
tumour tissue by immunohistochemistry. However, as an
invasive examination, tissue biopsy has obvious limita-
tions in the application of CEACAM1 as an early diag-
nosis marker in the clinic. Recently, soluble CEACAM1
has been found in body fluids, including saliva, serum,
seminal fluid, and bile [36,37]. However, there are few re-
ports concerning the diagnostic value of circulating
CEACAM1 in lung cancer patients, although the early
diagnosis of NSCLC is unsatisfactory.
In this study, we aimed to study whether CEACAM1
could discriminate lung cancer patients from health do-
nors [27]. ROC analysis showed that the AUC for
CEACAM1 remarkably exceeded 0.5 at 0.96, whichstrongly suggests the promising future of CEACAM1 as
a tumour monitor. Furthermore, 17 of 21 (81%) patients
showed high expression for CEACAM1 in lung tumours,
and CEACAM1 expression was restricted to neoplastic
epithelium, indicating that CEACAM1 was associated
with NSCLC. Although CEACAM1 mRNA levels did
not show a statistically significant difference between
tumour and normal lung tissues, the expression of
CEACAM1-S and the S/L ratios in tumour tissues
showed remarkable changes during oncogenesis.
Our results suggest that CEACAM1 is associated with
an increased risk for NSCLC and could reflect disease bur-
den (Figure 2A and Table 2). Based on the data of AUC,
the serum level of CEACAM1 ranked between that of
CEA and NSE and could provide complementary evidence
Table 3 Association between the CEACAM1 mRNA expression patterns and clinical parameters
Groups No. Tumour tissue Normal tissue
Median (P50) Range P value Median (P50) Range P value
Age
≥60 13 0.0293 5.60 × 10-4 ~ 0.0716 0.082 5.31 × 10-3 2.28 × 10-3 ~ 0.0172 0.828
<60 8 2.62 × 10-3 9.25 × 10-4 ~ 0.0287 6.99 × 10-3 3.80 × 10-4 ~ 0.0113
Sex
Male 12 3.09 × 10-3 5.60 × 10-4 ~ 0.0373 0.028* 4.31 × 10-3 3.80 × 10-4 ~ 0.0172 0.088
Female 9 0.0293 1.36 × 10-3 ~ 0.0716 8.67 × 10-3 3.81 × 10-3 ~ 0.0114
Staging***
Stage Ia ~ IIb 14 0.0126 5.60 × 10-4 ~ 0.0693 0.332 5.61 × 10-3 5.60 × 10-4 ~ 0.0693 0.709
Stage IIIa ~ IV 7 2.09 × 10-3 9.24 × 10-4 ~ 0.716 7.87 × 10-3 2.85 × 10-3 ~ 0.0113
Grading
G1 ~ 2 10 0.0126 1.04 × 10-3 ~ 0.716 0.439 8.60 × 10-3 3.20 × 10-3 ~ 0.172 0.020*
G3 ~ 4 11 3.21 × 10-3 5.60 × 10-4 ~ 0.422 3.81 × 10-3 3.80 × 10-4 ~ 0.0113
Histology
Squamous1 5 0.00144 9.246 × 10-4 ~ 0.0032 0.0032 3.80 × 10-4 ~ 0.0171
Adenocarcinoma 11 0.0286 0.0013 ~ 0.072 0.003* 0.00787 0.0034 ~ 0.0114 0.585
Others** 5 0.0021 5.60 × 10-4 ~ 0.014 0.00853 0.0023 ~ 0.011
Lymph node metastasis
node negative 7 0.0140 1.04 × 10-3 ~ 0.0658 0.502 8.53 × 10-3 3.81 × 10-3 ~ 0.017 0.117
node positive 14 3.19 × 10-3 5.60 × 10-4 ~ 0.0716 4.98 × 10-3 3.80 × 10-4 ~ 0.011
Invasion depth
pT1 ~ pT2 17 0.0129 5.60 × 10-4 ~ 0.0716 0.039* 2.12 × 10-3 3.80 × 10-4 ~ 0.0172 0.720
pT3 ~ pT4 4 1.63 × 10-3 9.25 × 10-4 ~ 3.21 × 10-3 6.28 × 10-3 2.85 × 10-3 ~ 0.0113
“1” represents squamous cell carcinoma; *P < 0.05.
“**” Others represents 2 poorly differentiated carcinomas, 1 mixed histology, 1 neuroendocrine carcinoma and 1 lymphoepithelioma-like carcinoma.
“***” 7th edition of the TNM classification of lung cancer by the International Association for the Study of Lung Cancer (IASLC).
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individuals with a cut off value, CEACAM1 demonstrated
hypersensitivity and a negative predictive value (Additional
file 2: Table S2), indicating that CEACAM1 may outper-
form both CEA and NSE as a biomarker. Moreover, the
change in serum CEACAM1 levels was more pronounced
in early tumours than in advanced tumours, which may be
of great clinical importance. As a result, our data demon-
strated that CEACAM1 might be a useful monitor for
NSCLC. However, it should be noted that because easy-Table 4 Expression patterns for the CEACAM1 S and L
forms in NSCLC tissues
Groups Median 95% CI P value
Tumour S-form (IOD) 15.89 11.95 ~ 60.44 0.023*
Normal S-form (IOD) 9.16 7.23 ~ 16.45
Tumour L-form (IOD) 10.43 8.05 ~ 14.58 0.917
Normal L-form (IOD) 10.45 7.92 ~ 13.60
Tumour (S:L) ratio 2.44 1.49 ~ 4.20 0.016*
Normal (S:L) ratio 0.96 0.86 ~ 1.28
*P < 0.05.to-diagnose patients are often enrolled in phase I studies,
our results may overestimate accuracy [28]. As we were
limited by sample size, future larger prospective studies
are needed to validate the prognostic value of serum
CEACAM1.
The origin of serum CEACAM1 in NSCLC remains un-
clear. Previous reports demonstrated that soluble
CEACAM1 could be produced by tumour cells and the
endothelial cells of angiogenic microvessels [19,38]. The
soluble CEACAM1 present in serum comprised mem
brane-bound isoforms and naturally occurring secreted
isoforms. The 3 isoforms of CEACAM1 were found to be
in their secreted form, contributing to the serum levels of
CEACAM1. Moreover, soluble CEACAM1 was present in
serum and has been reported to contain A2 domains [36],
corresponding to the membrane-bound isoforms of
CEACAM1-4L, CEACAM1-4S and the secreted isoform
CEACAM1-4C1. Moreover, it was further demonstrated
that apoptosis could induce cleavage of the intracellular
and extracellular domains of CEACAM1, resulting in an
increased level of soluble CEACAM1 [39]. All of these re-
ports have provided evidence of a number of sources of
Zhou et al. BMC Cancer 2013, 13:359 Page 9 of 10
http://www.biomedcentral.com/1471-2407/13/359soluble CEACAM1 in addition to the naturally occurring
secreted isoforms [39,40]. Based on the information men-
tioned above, soluble CEACAM1 may originate from
shedding or dead cells in addition to active secretion.
In a continuing study, we further analysed the expres-
sion and location of CEACAM1 in NSCLC tissues. By
immunohistochemistry, we found strong CEACAM1
staining present in 17 of 21 samples, with CEACAM1 ex-
pression localised to the neoplastic epithelium; there was
little/no staining in normal tissues. These results signifi-
cantly supported the up-regulation of CEACAM1 levels in
the serum of NSCLC patients. Although 15 of 21 cases
showed higher CEACAM1 mRNA levels in tumour tissues
than corresponding adjacent tumour-free tissues, no sta-
tistically significant difference was found with respect to
the mRNA expression level of CEACAM1 in these tissues.
The disparity in the CEACAM1 protein and RNA levels
in the present study may be due to the differential splicing
and proteolytic processing of CEACAM1 after transcrip-
tion, which needs to be verified in future.
Although there are discrepancies between our find-
ings and previous observations that CEACAM1 was re-
markably increased in cancerous tissues of the lung
compared with normal lung tissue [31,41], our add-
itional studies of the CEACAM1 S/L isoform expression
patterns were in accordance with previous reports. In
our research, the CEACAM1-S mRNA expression level
and the CEACAM1-S/CEACAM1-L (S: L) ratio were
significantly higher in tumour tissues than in normal
tissues. The expression of CEACAM1 on microvessels
in NSCLC was not found by immunohistochemical
staining [24], and human granulocytes, T cells and B
cells were reported to only express the CEACAM1-L
isoform without CEACAM1-S [42]. CEACAM1-S in the
NSCLC tumour tissues appeared to solely derive from
tumour cells, whereas CEACAM1-L may not. Thus, the
CEACAM1-S RNA levels and CEACAM1-S/L ratios,
which are increased in NSCLC, could closely reflect the
expression level of tumour cells. Our results indicated
that the expression of CEACAM1-S and the CEACA
M1-S/CEACAM1-L ratio could be changed without an
alteration in the CEACAM1 total expression levels of
CEACAM1 in NSCLC. It reinforced the hypothesis that
the tumour suppressive or oncogenic effects of
CEACAM1 were splice variant-dependent [9,35,43].
Conclusions
In conclusion, our study strongly suggests the potential
use of serum CEACAM1 and the tissue S/L ratio of
CEACAM1 as indicators for NSCLC diagnosis. Our re-
search indicated that CEACAM1 may originate from
tumour cells. Furthermore, the CEACAM1 isoform ex-
pression patterns could change even without changing
the quantity of CEACAM1 during oncogenesis.However, the involvement of CEACAM1 in NSCLC and
other cancers is complex, and further studies are required.
Many studies need to be performed to better understand
of the mechanisms that underlie our observations.
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